Characteristics of patients with follicular lymphoma
Characteristics . | IFN, no. (%) . | ASCT, no. (%) . | Total, no. (%) . |
|---|---|---|---|
| Patients evaluable | 126 (100.0) | 114 (100.0) | 240 (100.0) |
| Median age of evaluable patients, y [range] | 49.1 [26-59] | 49.1 [29-59] | |
| IPI* | |||
| Low risk | 74 (62.2) | 53 (54.1) | 127 (58.5) |
| Low-intermediate risk | 34 (28.6) | 38 (38.8) | 72 (33.2) |
| High-intermediate risk | 11 (9.2) | 7 (7.1) | 18 (8.3) |
| Male sex | 56 (44.4) | 62 (54.4) | 118 (49.2) |
| Stage IV | 93 (73.8) | 85 (74.6) | 178 (74.2) |
| Elevated serum LDH† | 27 (22.5) | 34 (34.3) | 61 (27.9) |
| ECOG greater than 1‡ | 10 (8.0) | 3 (2.7) | 13 (5.5) |
| B symptoms | 49 (38.9) | 38 (33.3) | 87 (36.3) |
| Induction therapy | |||
| MCP | 31 (24.6) | 28 (24.6) | 59 (24.6) |
| CHOP | 95 (75.4) | 86 (75.4) | 181 (75.4) |
Characteristics . | IFN, no. (%) . | ASCT, no. (%) . | Total, no. (%) . |
|---|---|---|---|
| Patients evaluable | 126 (100.0) | 114 (100.0) | 240 (100.0) |
| Median age of evaluable patients, y [range] | 49.1 [26-59] | 49.1 [29-59] | |
| IPI* | |||
| Low risk | 74 (62.2) | 53 (54.1) | 127 (58.5) |
| Low-intermediate risk | 34 (28.6) | 38 (38.8) | 72 (33.2) |
| High-intermediate risk | 11 (9.2) | 7 (7.1) | 18 (8.3) |
| Male sex | 56 (44.4) | 62 (54.4) | 118 (49.2) |
| Stage IV | 93 (73.8) | 85 (74.6) | 178 (74.2) |
| Elevated serum LDH† | 27 (22.5) | 34 (34.3) | 61 (27.9) |
| ECOG greater than 1‡ | 10 (8.0) | 3 (2.7) | 13 (5.5) |
| B symptoms | 49 (38.9) | 38 (33.3) | 87 (36.3) |
| Induction therapy | |||
| MCP | 31 (24.6) | 28 (24.6) | 59 (24.6) |
| CHOP | 95 (75.4) | 86 (75.4) | 181 (75.4) |